South and Central America Diltiazem Market Key Companies and SWOT Analysis by 2028
Historic Data: 2019-2020 | Base Year: 2021 | Forecast Period: 2022-2028South and Central America Diltiazem Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product Type (Capsules, Injection, and Tablets) and Application (Angina, Hypertension, and Others)
- Report Date : Oct 2021
- Report Code : TIPRE00025363
- Category : Life Sciences
- Status : Published
- Available Report Formats :
- No. of Pages : 134
The South and Central America diltiazem market is expected to reach US$ 57.03 million in 2028 from US$ 26.82 million in 2021; it is estimated to grow at a CAGR of 11.4% from 2021 to 2028.
Rise in government initiatives for promotion, increase in the prevalence of cardiovascular diseases, and rise in the elderly population with heart diseases worldwide are expected to boost the market growth over the years. However, the side effects of Diltiazem on consumption are likely to impact the market's growth in the coming years negatively.
Diltiazem has potential use in a wide variety of cardiovascular disorders. According to the World Health Organization, cardiovascular diseases (CVDs) are the number one cause of death worldwide. CVDs are a major cause of morbidity and affect more people than any other disease. Tobacco consumption, unhealthy diet, and physical inactivity are major lifestyle factors that increase the risk of heart attacks and strokes. In addition, other risk factors that can lead to cardiovascular diseases are high blood pressure, diabetes, and increased cholesterol levels. The calcium channel blockers diltiazem (Cardizem) and verapamil (Calan and Apoptin) effectively control the initial ventricular rate in patients with atrial fibrillation. These agents are given intravenously in bolus doses until the ventricular rate becomes slower.
Furthermore, Diltiazem reduces conduction in the atrioventricular node, which is also useful for heart rate control in patients with atrial fibrillation. Thus, the increasing prevalence of atrial fibrillation across the globe drives the diltiazem market. According to the Global Ageing 2019 survey, the world's population of 65 and above totaled 703 million in 2019. The elderly demographic is expected to double to 1.5 billion people by 2050. Also, the elderly population is more prompt to have atypical presentations, comorbid conditions, and unfavorable outcomes. Structural and functional changes in the cardiovascular system associated with aging are major causes of cardiovascular diseases. Therefore, the rising geriatric population worldwide is leading to an increase in the incidence of cardiovascular disease, bolstering the growth of the diltiazem market.
The COVID-19 outbreak has stringently affected medical services in South and Central America. The sudden outbreak of COVID-19 led to the implementation of stringent lockdown regulations across several nations, resulting in disruptions in import and export activities of Diltiazem. Also, the countries are famous for medical tourism, which is also influenced by the pandemic. It is anticipated that the region will likely force a second lockdown, which will ultimately hamper the healthcare industry in the area. There have been intensive attempts to explore drug therapy to prevent and treat SARS-CoV-2 infection during this COVID-19 pandemic. Thus, the ongoing clinical studies regarding Diltiazem for treatment in COVID-19 in the region are likely to favor the market's growth moderately.
- This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
SOUTH AND CENTRAL AMERICA DILTIAZEM MARKET SEGMENTATION
By Product Type
- Tablet
- Capsules
- Injection
By Application
- Hypertension
- Angina
- Others
By Country
- Brazil
- Argentina
- Rest of South and Central America
Company Profiles
- Bausch Health Companies Inc.
- Teva Pharmaceutical Industries Ltd
- MYLAN N.V.
- Pfizer Inc.
- Sandoz (Novartis AG)
- Sun Pharmaceutical Industries Ltd
- Hikma Pharmaceuticals PLC
- Zydus Cadila
- Glenmark
South and Central America Diltiazem Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 26.82 Million |
| Market Size by 2028 | US$ 57.03 Million |
| Global CAGR (2021 - 2028) | 11.4% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Product Type
|
| Regions and Countries Covered | South and Central America
|
| Market leaders and key company profiles |
Market Research & Consulting
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Testimonials
I wish to appreciate your support and the professionalism you displayed in the course of attending to my request for information regarding to infectious disease IVD market in Nigeria. I appreciate your patience, your guidance, and the fact that you were willing to offer a discount, which eventually made it possible for us to close a deal. I look forward to engaging The Insight Partners in the future, all thanks to the impression you have created in me as a result of this first encounter.
DR CHIJIOKE ONYIA MANAGING DIRECTOR, PineCrest Healthcare Ltd.
The Insight Partners delivered insightful, well-structured market research with strong domain expertise. Their team was professional and responsive throughout. The user-friendly website made accessing industry reports seamless. We highly recommend them for reliable, high-quality research services
YUKIHIKO ADACHI CEO, Deep Blue, LLC.
We worked with The Insight Partners for an important market study and forecast. They gave us clear insights into opportunities and risks, which helped shape our plans. Their research was easy to use and based on solid data. It helped us make smart, confident decisions. We highly recommend them.
PIYUSH NAGPAL Sr. Vice President, Market Research
The research report delivered details on drivers and restraints, trends, and opportunities, along with strategic activities in the market. Previously, we were struggling to get reliable information.
Manager Medical Devices ManufacturingReason to Buy
- Informed Decision-Making
- Understanding Market Dynamics
- Competitive Analysis
- Identifying Emerging Markets
- Customer Insights
- Market Forecasts
- Risk Mitigation
- Boosting Operational Efficiency
- Strategic Planning
- Investment Justification
- Tracking Industry Innovations
- Aligning with Regulatory Trends
Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.
Absolutely — analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.
Once your order is successfully placed, you will receive a confirmation email along with your invoice.
• For published reports: You’ll receive access to the report within 4–6 working hours via a secured email sent to your email.
• For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.
We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we’ll be happy to provide a customized proposal or scope.
The report is available in either PDF format or as an Excel dataset, depending on the license you choose.
The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
Please review the license options at checkout or contact us to confirm which formats are included with your purchase.
Our payment process is fully secure and PCI-DSS compliant.
We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
You can make your purchase with confidence, knowing your personal and financial information is safe with us.
Yes, we do offer special pricing for bulk purchases.
If you're interested in purchasing multiple reports, we’re happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you’re considering, and we’ll share a personalized quote.
Yes, absolutely.
Our team is available to help you make an informed decision. Whether you have questions about the report’s scope, methodology, customization options, or which license suits you best, we’re here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.
Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we’ll be happy to assist.
Yes, certainly.
If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we’ll ensure the issue is resolved quickly so you can access your report without interruption.
- Bausch Health Companies Inc.
- Teva Pharmaceutical Industries Ltd
- MYLAN N.V.
- Pfizer Inc.
- Sandoz (Novartis AG)
- Sun Pharmaceutical Industries Ltd
- Hikma Pharmaceuticals PLC
- Zydus Cadila
- Glenmark
Get Free Sample For